002620 — Jeil Pharma Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapValue Trap

Annual income statement for Jeil Pharma Holdings, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	762,568	792,965	804,043	779,822	657,614
Cost of Revenue
Gross Profit	180,507	180,483	214,584	206,521	253,498
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Total Operating Expenses	786,423	878,848	811,826	836,585	618,119
Operating Profit	-23,855	-85,883	-7,783	-56,763	39,495
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-6,129	-83,861	-13,982	-61,626	39,365
Provision for Income Taxes
Net Income After Taxes	-12,870	-83,145	-13,241	-66,391	34,647
Minority Interest
Net Income Before Extraordinary Items
Net Income	-3,482	-74,556	-16,250	-51,159	14,635
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-3,482	-74,556	-16,250	-51,159	14,635
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	402	-1,541	152	-1,419	906
Dividends per Share